Management of acquired aplastic anemia in children

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 191-195

  Korthof, E T ^a   Bekassy A N ^b   Hussein, A A ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

acquired aplastic anemia; childhood; hematopoietic SCT; immunosuppressive therapy; management; supportive care

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DANAZOL; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

APLASTIC ANEMIA; BONE MARROW TRANSPLANTATION; CANCER PROGNOSIS; CANCER RECURRENCE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHENOTYPE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS;

EID: 84873443351     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.235     Document Type: Review

References (60)

1. Guinan EC. Diagnosis and management of aplastic anemia. Hematol Am Soc Hematol Educ Program 2011; 2011: 76-81
2. Chessells JM. Pitfalls in the diagnosis of childhood leukemia. Br J Haematol 2001; 114: 506-511
3. Afable MG, Tiu RV, Maciejewski J. Clonal evolution in aplastic anemia. Hematol Am Soc Hematol Educ Program 2011; 2011: 90-95
4. Niemeyer C, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program 2011; 2011: 84-89
5. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anemia. Br J Haematol 2009; 147: 43-70
6. Alter BP. Current diagnosis of inherited bone marrow failure syndromes. Pediatr Hematol Oncol 2007; 24: 87-99
7. Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica 2010; 95: 1236-1240
8. Afable MG, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV et al. SNP array-based karyo-typing: Differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood 2011; 117: 6876-6884
9. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002; 100: 786-790
10. Pu JJ, Mukhina G, Wang H, Savage WJ, Brodsky RA. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol 2011; 87: 37-45
11. Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia. Pathol Int 2008; 58: 353-360
12. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129-3135
13. Maciejewski JP, Risitano A. Hematopoietic stem cells in aplastic anemia. Arch Med Res 2003; 34: 520-527
14. Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol 2008; 15: 162-168
15. DeZern AE, Guinan EC. Therapy for aplastic anemia. Hematol Am Soc Hematol Educ Program 2011; 2011: 82-83
16. Bacigalupo A, Passweg J. Diagnosis and treatment of acquired aplastic anemia. Hematol Oncol Clin North Am 2009; 23: 159-170
17. Valdez JM, Scheinberg P, Young NS, Walsh T. Infections in patients with aplastic anemia. Semin Hematol 2009; 46: 269-276
18. Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anemia in children. Br J Haematol 2007; 136: 549-564
19. Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM et al. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol 2010; 150: 377-379
20. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO et al. Granulocyte transfusions in severe aplastic anemia: An eleven-year experience. Haematologica 2009; 94: 1661-1668
21. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116: 2448-2454
22. Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-494
23. Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008; 42: 799-805
24. Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK et al. The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol 2009; 2: 44
25. Koh KN, Park M, Kim BE, Im HJ, Seo JJ. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia. J Pediatr Hematol Oncol 2010; 32: 611-614
26. Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-323
27. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: A report from the European Group for Blood and Marrow Transplantation. Haematologica 2007; 92: 11-18
28. Scheinberg P, Wu CO, Nunez O, Young NS. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr 2008; 153: 814-819
29. Passweg JR, Marsh JCW. Aplastic Anemia: First line Treatment by Immunosuppression and Sibling Marrow Transplantation. Hematol Am Soc Hematol Educ Program Hematol 2010; 153: 36-42
30. Kojima S, Horibe K, Inaba J, Yoshimi A, Takahashi Y, Kudo K et al. Long-term outcome of acquired aplastic anemia in children: Comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 2000; 111: 321-328
31. Unal S, Cetin M, Tavil B, Calskan N, Calişkan N, Yetgin S et al. Favorable outcome with allogeneic hematopoietic stem cell transplantation in pediatric acquired aplastic anemia patients. Pediatr Transpl 2007; 11: 788-791
32. Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant 2009; 15: 279-292
33. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110: 1397-1400
34. Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Dührsen U et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: A study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 2011; 117: 4434-4441
35. Be'ka'ssy NA, Locasciulli A, Marsh JCV, Socié G, Fuehrer M, Passweg J. Immunosuppression with ALG and CsA is first line treatment in children with SAA lacking an HLA identical sibling. Pediatr Blood Cancer 2006; 45: 359-360
36. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430-438
37. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: A single-center retrospective study. Ann Hematol 2010; 89: 851-859
38. Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J et al. Cyclosporin A response and dependence in children with acquired aplastic anemia: A multicentre retrospective study with long-term observation follow-up. Br J Haematol 2008; 140: 197-205
39. Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M et al. Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy - systematic review and meta-analysis. Haematologica 2009; 94: 712-719
40. Führer M, Rampf U, Baumann I, Faldum A, Niemeyer C, Janka-Schaub G et al. Immunosuppressive therapy for aplastic anemia in children: A more severe disease predicts better survival. Blood 2005; 106: 2102-2104
41. Yoshida N, Yagasaki H, Hama A, Takahashi Y, Kosaka Y, Kobayashi R et al. Predicting response to immunosuppressive therapy in childhood aplastic anemia. Haematologica 2011; 96: 771-774
42. Pongtanakul B, Das PK, Charpentier K, Dror Y. Outcome of children with aplastic anemia treated with immunosuppressive therapy. Pediatr Blood Cancer 2008; 50: 52-57
43. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A. Treatment of aplastic anemia with granulocyte-colony stimulating factor and risk of malignancy. Italian Aplastic Anemia Study Group. Lancet 2001; 357: 43-44
44. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anemia with combined immunosuppression: Anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133: 606-611
45. Scheinberg P, Wu CO, Nunez O, Boss C, Sloand EM, Young NS. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: A prospective randomized study. Haematologica 2009; 94: 348-354
46. Selleri C, Serio B, Risitano AM. Novel immunosuppressive strategies for bone marrow failure syndromes: A focus on alemtuzumab. Mini Rev Med Chem 2011; 11: 536-543
47. Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anemia. Br J Haematol 2006; 133: 622-627
48. Kamio T, Ito E, Ohara A, Kosaka Y, Tsuchida M, Yagasaki H et al. Relapse of aplastic anemia in children after immunosuppressive therapy: A report from the Japan Childhood Aplastic Anemia Study Group. Haematologica 2011; 96: 814-819
49. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111: 1054-1059
50. Eapen M, Horowitz M. Alternative donor transplantation for aplastic anemia. Hematol Am Soc Hematol Educ Program 2010; 2010: 43-46
51. Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: A retrospective study from the EBMT-SAA working party. Haematologica 2010; 95: 976-982
52. Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41: 45-50
53. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. BBMT 2011; 12: 1277-1284
54. Perez-Albuerne ED, Eapen M, Klein J, Gross TJ, Lipton JM, Baker KS et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol 2008; 141: 216-223
55. Jaing TH, Huang IA, Chen SH, Yang CP, Liang DC, Hung IJ. Cord blood transplantation in children with relapsed or refractory severe aplastic anemia. J Pediatr Hematol Oncol 2011; 33: 18-21
56. Yoshimi A, Kojima S, Taniguchi S, Hara J, Matsui T, Takahashi Y et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2008; 14: 1057-1063
57. Li Y, Li X, Ge M, Shi J, Qian L, Zheng Y et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience. Ann Hematol 2011; 90: 529-537
58. Ades L, Mary J-Y, Robin M, Ferry C, Porcher R, Esperou H et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood 2004; 103: 2490-249
59. Eapen M, Ramsay NKC, Mertens AC, Robison LL, DeFor T, Davies SM. Late outcomes after bone marrow transplant for aplastic anemia. Br J Haematol 2000; 111: 754-760
60. Mohty B, Mohty M. Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: An update. Blood Cancer J 2011; 1: E16